{"nctId":"NCT01387672","briefTitle":"Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study","startDateStruct":{"date":"2011-09"},"conditions":["Osteoporosis"],"count":265,"armGroups":[{"label":"Nitrol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nitrates (NABT Main trial)"]},{"label":"Nitro-Dur","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nitrates (NABT Main trial)"]},{"label":"Nitrostat 1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nitrates (NABT Main trial)"]},{"label":"Nitrostat 2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nitrates (NABT Main trial)"]},{"label":"ISMO","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Nitrates (NABT Main trial)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Nitrates (NABT Main trial)","otherNames":["NABT-B Sub-Study: Nitroglycerin Ointment 2%: 15mg of NTG ointment for a 3 month period"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nNABT:\n\n* Women aged 50 years and older whose last menstrual period occurred at least 3 years ago\n* Women without a uterus will be eligible after age 55\n\nNABT-B:\n\n* Women aged 50 years and older whose last menstrual period occurred at least 3 years ago\n* Women without a uterus will be eligible after age 55\n* Previously treated with alendronate but stopped within 2 years of study commencement; or previously treated with risedronate but stopped within 1 year of study commencement; or previously treated with zoledronate.\n\nExclusion Criteria:\n\nNABT:\n\n* A previous fracture of the hip, wrist, spine or ankle within the last 3 months; or a diagnosis of osteoporosis;\n* A history of bone disorders such as hyperparathyroidism or Paget's disease;\n* Treatment within 12 months of study entry with any agent that may influence bone metabolism including any hormone, anti-estrogen or raloxifene and prednisone (equivalent to 5 mg/d for 12 months or greater);\n* Treatment with any antiresorptive agent, including alendronate, risedronate, etidronate or denosumab use for at least four weeks within the last three years;\n* Previous treatment with intravenous zoledronate or parathyroid hormone;\n* Current treatment with nitrates;\n* A history of migraine headaches;\n* A history of angina or cardiovascular disease;\n* Inability to give informed consent;\n* Hypersensitivity to nitroglycerin.\n\nNABT-B:\n\n* A previous fracture of the hip, wrist, spine or ankle; or a self-reported diagnosis of osteoporosis;\n* A history of bone disorders such as hyperparathyroidism or Paget's disease;\n* Treatment within 12 months of study entry with any agent that may influence bone metabolism including any hormone, anti-estrogen or raloxifene and prednisone (equivalent to 5 mg/d for 12 months or greater);\n* Treatment with etidronate or denosumab use for at least four weeks within the last three years and any previous treatment with parathyroid hormone;\n* Current treatment with nitrates;\n* A history of migraine headaches;\n* A history of angina or cardiovascular disease;\n* Inability to give informed consent;\n* Hypersensitivity to nitroglycerin.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Bone Turnover Markers","description":"Markers of Bone Formation:\n\n* Serum Procollagen type 1 amino- terminal propeptide (P1NP)\n* Serum Osteocalcin (OC)\n* Serum Bone-specific alkaline phosphatase (BALP)\n\nMarkers of Bone Resorption:\n\n\\- Serum C-telopeptides of collagen cross-links (CTX)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.627","spread":"16.191"},{"groupId":"OG001","value":"-0.405","spread":"20.289"},{"groupId":"OG002","value":"-4.297","spread":"16.236"},{"groupId":"OG003","value":"-6.126","spread":"16.093"},{"groupId":"OG004","value":"2.941","spread":"36.843"},{"groupId":"OG005","value":"-1.635","spread":"16.749"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.244","spread":"12.049"},{"groupId":"OG001","value":"3.796","spread":"33.601"},{"groupId":"OG002","value":"-4.481","spread":"14.823"},{"groupId":"OG003","value":"1.046","spread":"21.818"},{"groupId":"OG004","value":"1.033","spread":"17.931"},{"groupId":"OG005","value":"4.247","spread":"22.088"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.023","spread":"11.824"},{"groupId":"OG001","value":"-0.541","spread":"20.738"},{"groupId":"OG002","value":"-7.426","spread":"11.056"},{"groupId":"OG003","value":"-7.000","spread":"19.011"},{"groupId":"OG004","value":"-3.686","spread":"17.435"},{"groupId":"OG005","value":"-1.648","spread":"21.523"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.844","spread":"26.084"},{"groupId":"OG001","value":"-1.025","spread":"32.163"},{"groupId":"OG002","value":"-9.699","spread":"27.299"},{"groupId":"OG003","value":"-0.666","spread":"37.945"},{"groupId":"OG004","value":"-1.380","spread":"52.248"},{"groupId":"OG005","value":"-1.783","spread":"28.063"}]}]}]},{"type":"SECONDARY","title":"Headache","description":"Severity of headaches. Subjects recorded the severity of headaches upon awakening every day during the run-in phase using a visual analogue scale (VAS). The scale is represented by a line (continuum) 10 cm long. Subjects were asked to make a vertical line along the continuum to indicate the severity of their headache each morning upon awakening. The score is recorded in cm from \"0\" to \"10\". A vertical line marked at \"0\" means no headache (score recorded = \"0\"), a vertical line marked at \"10\" means a terrible headache (score recorded = \"10\").","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"2.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"2.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"2.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"1.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.62"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":39},"commonTop":["Headache","Dizziness","Nausea"]}}}